SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Wedbush Says Sarepta Biomarker Data Will Be in Focus

Wedbush highlighted Sarepta Therapeutics' PD biomarker data from FSHD and DM1 studies.

SRPT

Related stories